Page last updated: 2024-11-05

troglitazone and Glucose Intolerance

troglitazone has been researched along with Glucose Intolerance in 17 studies

Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.

Glucose Intolerance: A pathological state in which BLOOD GLUCOSE level is less than approximately 140 mg/100 ml of PLASMA at fasting, and above approximately 200 mg/100 ml plasma at 30-, 60-, or 90-minute during a GLUCOSE TOLERANCE TEST. This condition is seen frequently in DIABETES MELLITUS, but also occurs with other diseases and MALNUTRITION.

Research Excerpts

ExcerptRelevanceReference
"The primary purpose of this study was to assess the effects of 12 weeks of treatment with either troglitazone, an investigational thiazolidinedione that acts as an insulin-action enhancer, or placebo in patients with impaired glucose tolerance (IGT)."9.08Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone. ( Antonucci, T; Lockwood, D; McLain, R; Norris, RM; Whitcomb, R, 1997)
" Studies and abstracts chosen summarize the clinical action of troglitazone in healthy volunteers, in subjects with impaired glucose tolerance, and in patients with diabetes mellitus."8.80Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus. ( Campbell, LK; Campbell, RK; Johnson, MD, 1998)
" Therapy was directed primarily at decreasing insulin resistance and thereby improving glucose intolerance by the administration of troglitazone, which increases insulin sensitivity."7.70Troglitazone ameliorates insulin resistance in a diabetic patient with Prader-Willi syndrome. ( Fujii, S; Fujita, K; Ishii, T; Kurimasa, H; Mori, T; Sato, T; Tanaka, S; Yamakita, T; Yoshioka, K, 1998)
" Oral glucose tolerance tests (OGTTs) and frequently sampled intravenous glucose tolerance tests (FSIGTs) were conducted on Latino women with impaired glucose tolerance and a history of gestational diabetes before and after 12 weeks of treatment with 400 mg/day troglitazone (n = 13) or placebo (n = 12)."5.09Response of pancreatic beta-cells to improved insulin sensitivity in women at high risk for type 2 diabetes. ( Azen, SP; Berkowitz, K; Buchanan, TA; Goico, J; Kjos, SL; Marroquin, A; Ochoa, C; Peters, RK; Xiang, AH, 2000)
"We conducted a randomized placebo-controlled study to determine the effects of the thiazolidinedione compound troglitazone on whole-body insulin sensitivity (SI), pancreatic beta-cell function, and glucose tolerance in 42 Latino women with impaired glucose tolerance (IGT) and a history of gestational diabetes mellitus (GDM), characteristics that carry an 80% risk of developing NIDDM within 5 years."5.08Effect of troglitazone on insulin sensitivity and pancreatic beta-cell function in women at high risk for NIDDM. ( Azen, S; Berkowitz, K; Buchanan, TA; Dunn, ME; Goico, J; Kjos, SL; Marroquin, A; Peters, R; Xiang, A, 1996)
"The primary purpose of this study was to assess the effects of 12 weeks of treatment with either troglitazone, an investigational thiazolidinedione that acts as an insulin-action enhancer, or placebo in patients with impaired glucose tolerance (IGT)."5.08Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone. ( Antonucci, T; Lockwood, D; McLain, R; Norris, RM; Whitcomb, R, 1997)
" Studies and abstracts chosen summarize the clinical action of troglitazone in healthy volunteers, in subjects with impaired glucose tolerance, and in patients with diabetes mellitus."4.80Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus. ( Campbell, LK; Campbell, RK; Johnson, MD, 1998)
" Metformin, an antihyperglycemic drug of the biguanide class, may be effective in subjects with IGT by reducing hepatic glucose output, enhancing insulin sensitivity, or through other mechanisms such as weight loss."4.79[Drug therapy in subjects with impaired glucose tolerance]. ( Kawamori, R; Yoshii, H, 1996)
" The occult diabetic group had an abnormal response to hyperemia before the treatment with troglitazone and showed little change in flow after BA occlusion."3.70Insulin action enhancement normalizes brachial artery vasoactivity in patients with peripheral vascular disease and occult diabetes. ( Avena, R; Curry, KM; Mitchell, ME; Nylen, ES; Sidawy, AN, 1998)
" Therapy was directed primarily at decreasing insulin resistance and thereby improving glucose intolerance by the administration of troglitazone, which increases insulin sensitivity."3.70Troglitazone ameliorates insulin resistance in a diabetic patient with Prader-Willi syndrome. ( Fujii, S; Fujita, K; Ishii, T; Kurimasa, H; Mori, T; Sato, T; Tanaka, S; Yamakita, T; Yoshioka, K, 1998)
" The objective of this study was to examine the impact of chronic use of an insulin sensitizer on glucose metabolism in normal glucose tolerant AA at risk for DM (previous gestational diabetes mellitus [GDM] or first-degree relative with DM)."2.71The impact of an insulin sensitizer, troglitazone, on glucose metabolism in African Americans at risk for type 2 diabetes mellitus: a placebo-controlled, 24-month randomized study. ( Gaillard, T; Habash, D; Osei, K; Rhinesmith, S; Schuster, D, 2003)

Research

Studies (17)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's10 (58.82)18.2507
2000's7 (41.18)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Pugeat, M1
Schuster, D1
Gaillard, T1
Rhinesmith, S1
Habash, D1
Osei, K1
Schröder, AK1
Tauchert, S1
Ortmann, O1
Diedrich, K1
Weiss, JM1
Xiang, AH2
Peters, RK2
Kjos, SL3
Goico, J3
Ochoa, C2
Marroquin, A3
Tan, S1
Hodis, HN1
Azen, SP2
Buchanan, TA3
Ehrmann, DA2
Berkowitz, K2
Peters, R1
Dunn, ME1
Xiang, A1
Azen, S1
Henry, RR1
Kawamori, R1
Yoshii, H1
Antonucci, T1
Whitcomb, R1
McLain, R1
Lockwood, D1
Norris, RM1
Cavaghan, MK1
Byrne, MM1
Polonsky, KS1
Linday, LA1
Yoshioka, K2
Yokoo, S1
Yoshida, T1
Kondo, M1
Johnson, MD1
Campbell, LK1
Campbell, RK1
Avena, R1
Mitchell, ME1
Nylen, ES1
Curry, KM1
Sidawy, AN1
Yamakita, T1
Ishii, T1
Mori, T1
Sato, T1
Tanaka, S1
Kurimasa, H1
Fujita, K1
Fujii, S1
Nakamura, T1
Funahashi, T1
Yamashita, S1
Nishida, M1
Nishida, Y1
Takahashi, M1
Hotta, K1
Kuriyama, H1
Kihara, S1
Ohuchi, N1
Nishimura, T1
Kishino, BI1
Ishikawa, K1
Kawamoto, T1
Tokunaga, K1
Nakagawa, C1
Mineo, I1
Watanabe, F1
Tarui, S1
Matsuzawa, Y1

Clinical Trials (10)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Efficacy and Safety of Furocyst in Patients With Poly Cystic Ovary Syndrome[NCT02789488]Phase 450 participants (Actual)Interventional2013-09-30Completed
Descriptive, Transversal Study of Evaluation of Cardiovascular Risks Factors and Prevalence of Metabolic Syndrome in the Different Phenotypes of Women With Polycystic Ovary Syndrome[NCT00784615]80 participants (Anticipated)Observational2007-12-31Recruiting
Clinical Metabolic and Endocrine Parameters in Response to Metformin and Lifestyle Intervention in Women With Polycystic Ovary Syndrome: A Phase 4 Randomized, Double- Blind and Placebo Control Trial[NCT00679679]Phase 430 participants (Actual)Interventional2003-01-31Completed
Anxiety and Sexual Malfunction in Infertile Polycystic Ovarian Syndrome Patients[NCT05056272]128 participants (Anticipated)Observational2022-01-01Recruiting
The Impact of Continuous Aerobic Exercise and High-Intensity Interval Training on Reproductive Outcomes in Polycystic Ovary Syndrome: A Pilot Randomized Controlled Trial.[NCT03362918]60 participants (Actual)Interventional2018-01-01Completed
Adipose Tissue Angiogenesis in Polycystic Ovary Syndrome (PCOS)[NCT01745471]36 participants (Anticipated)Observational2012-12-06Active, not recruiting
The Effects of Contraceptive Pill and Hormonal Vaginal Ring on Hormonal, Inflammatory and Metabolic Parameters in Women of Reproductive Age With Polycystic Ovary Syndrome (PCOS).[NCT01588873]Phase 442 participants (Anticipated)Interventional2012-04-30Recruiting
Rosiglitazone Intervention Study in Patients With Type 1.5 Diabetes[NCT00194896]64 participants (Actual)Interventional2000-02-29Completed
Modulation of Insulin Secretion and Insulin Sensitivity in Bangladeshi Type 2 Diabetic Subjects by an Insulin Sensitizer Pioglitazone and T2DM Association With PPARG Gene Polymorphism.[NCT01589445]Phase 477 participants (Actual)Interventional2008-11-30Completed
Effect of Gain on Closed-Loop Insulin[NCT02065895]8 participants (Actual)Interventional2013-12-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Patients Positive for T Cell Responses to Islet Proteins at 36 Months.

Number of participants positive for T cell reactivity to islet proteins at 36 months. (NCT00194896)
Timeframe: 36 months

Interventionparticipants (Number)
Rosiglitazone Autoantibody Positive1
Rosiglitazone Autoantibody Negative2
Glyburide Autoantibody Positive2
Glyburide Autoantibody Negative3

Changes in Beta Cell Function Assessed by Fasting and Stimulated C-peptide Measured at 36 Months.

Changes in beta cell function assessed by fasting and stimulated C-peptide measured at 36 months. (NCT00194896)
Timeframe: 36 months

,,,
Interventionng per ml (Mean)
Fasting C-peptideGlucagon Stimulated C-peptide
Glyburide Autoantibody Negative0.30.3
Glyburide Autoantibody Positive0.13.1
Rosiglitazone Autoantibody Negative-1.4-2.8
Rosiglitazone Autoantibody Positive-0.4-0.6

Comparison of Changes in Fasting Serum Glucose (FSG)With Pioglitazone and Metformin

Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug

,
Interventionmmol/l (Mean)
Baseline FSG3rd Month FSG
Metformin ( 002 Group)6.26.5
Pioglitazone (001 Group)6.95.4

Comparison of Changes in Fasting Serum Insulin (FSI)With Pioglitazone and Metformin

Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug

,
InterventionμU/ml (Mean)
Baseline FSI3rd month FSI
Metformin ( 002 Group)13.013.9
Pioglitazone (001 Group)16.212.3

Comparison of Changes in Glycosylated Hemoglobin (HbA1c)With Pioglitazone and Metformin

Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug

,
Interventionpercentage (Mean)
Baseline HbA1c3rd month HbA1c
Metformin ( 002 Group)7.87.0
Pioglitazone (001 Group)7.36.7

Comparison of Changes in HOMA Percent B and HOMA Percent S With Pioglitazone and Metformin

"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostatic Model Assessment of Beta cell function(HOMA percent B) Analysis 2: Homeostatic Model Assessment of Insulin Sensitivity (Homa percent S)" (NCT01589445)
Timeframe: 3 months for each drug

,
Interventionpercentage (Mean)
Baseline HOMA percent beta cells function3rd month HOMA percent beta cells functionBaseline HOMA percent sensitivity3rd month HOMA percent sensitivity
Metformin ( 002 Group)109.3116.076.267.2
Pioglitazone (001 Group)118.9132.351.169.3

Comparison of Changes in Insulin Levels (HOMA IR,QUICKI) With Pioglitazone and Metformin

"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostasis Model Assessment Insulin Resistance(HOMA IR) Analysis 2: Quantitative Insulin sensitivity Check Index(QUICKI)" (NCT01589445)
Timeframe: 3 months for each drug

,
InterventionScore on a scale ( SI unit) (Mean)
Baseline QUICKI3rd month QUICKIBaseline HOMA IR3rd month HOMA IR
Metformin ( 002 Group)0.570.543.74.3
Pioglitazone (001 Group)0.520.595.12.9

Comparison of Changes in Lipid Profiles With Pioglitazone and Metformin

"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1:Total Cholesterol(TC) Analysis 2:Triglyceride(TG) Analysis 3:High Density Lipoprotein(HDL) Analysis 4:Low Density Lipoprotein(LDL)" (NCT01589445)
Timeframe: 3 months for each drug

,
Interventionmg/dl (Mean)
Baseline TC3rd month TCBaseline TG3rd month TGBaseline HDL3rd month HDLBaseline LDL3rd month LDL
Metformin (002 Group)193.0177.0166.0175.034.434.7125.6112.0
Pioglitazone (001 Group)182.01781831953333.2112.8105.5

Glucose Area Under the Curve (AUC) Breakfast

Glucose Area Under the Curve (AUC) Breakfast defines the total exposure to glucose during breakfast. Breakfast is typically considered the most difficult meal to control; low AUC is desirable.This outcome measure was analyzed for each of the three calibration error values (high error, no error and low error). (NCT02065895)
Timeframe: On day #1, day #2 and day #3 (each day could be 24 hours to 7 days apart from prior one, and completed within 6 week period) 8:00 AM to 2:00 PM on day following admission, with samples obtained every 10-15 minutes, for each sequence of calibration errors

Interventionmmol/l/min (Mean)
HIGH Error66.8
NO Error48.8
LOW Error37.4

Nighttime Time-in-target 5.0-8.33mmol/l (Controller Set-point Plus and Minus 15 mg/dL)

Night-time in target range 5.0-8.33, following the 3 hour controller initialization period blood glucose remained at or near target. (NCT02065895)
Timeframe: On day #1, day #2 and day #3 (each day could be 24 hours to 7 days apart from prior one, and completed within 6 week period) 12:00 AM to 6:00 AM on day following admission, with samples obtained every 10-15 minutes, for each sequence of calibration errors

Interventionpercentage of time in target range (Median)
HIGH Error88
NO Errror100
LOW Error80

Peak and Nadir Postprandial Glucose Concentration

Highest and lowest glucose concentrations obtained during breakfast meal. (NCT02065895)
Timeframe: On day #1, day #2 and day #3 (each day could be 24 hours to 7 days apart from prior one, and completed within 6 week period) 8:00 AM to 12:00 PM on day following admission, with samples obtained every 10-15 minutes, for each sequence of calibration errors

,,
Interventionmmol/l (Mean)
Peak glucose concentrationNadir glucose concentration
Gain Decreased and Target Increased11.36.6
Gain Increased and Target Decreased13.34.5
Nadir Mean11.84.8

Reviews

6 reviews available for troglitazone and Glucose Intolerance

ArticleYear
[Treatment of PCOS without IVF: weight loss, insulin-sensitizing agents].
    Journal de gynecologie, obstetrique et biologie de la reproduction, 2003, Volume: 32, Issue:3 Pt 2

    Topics: Acarbose; Chromans; Enzyme Inhibitors; Female; Glucose Intolerance; Glucosidases; Humans; Hypoglycem

2003
[Insulin resistance in polycystic ovary syndrome].
    Wiener klinische Wochenschrift, 2003, Dec-15, Volume: 115, Issue:23

    Topics: Adolescent; Adult; Body Mass Index; Cardiovascular Diseases; Chromans; Controlled Clinical Trials as

2003
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Polycystic ovary syndrome.
    The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12

    Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet

2005
Effects of troglitazone on insulin sensitivity.
    Diabetic medicine : a journal of the British Diabetic Association, 1996, Volume: 13, Issue:9 Suppl 6

    Topics: Animals; Blood Glucose; Blood Pressure; Chromans; Diabetes Mellitus, Type 2; Glucose Intolerance; Gl

1996
[Drug therapy in subjects with impaired glucose tolerance].
    Nihon rinsho. Japanese journal of clinical medicine, 1996, Volume: 54, Issue:10

    Topics: Acarbose; Biguanides; Chromans; Diabetes Mellitus, Type 2; Glucose Intolerance; Glycoside Hydrolase

1996
Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus.
    The Annals of pharmacotherapy, 1998, Volume: 32, Issue:3

    Topics: Animals; Chromans; Clinical Trials as Topic; Diabetes Mellitus; Glucose Intolerance; Humans; Hypogly

1998

Trials

8 trials available for troglitazone and Glucose Intolerance

ArticleYear
The impact of an insulin sensitizer, troglitazone, on glucose metabolism in African Americans at risk for type 2 diabetes mellitus: a placebo-controlled, 24-month randomized study.
    Metabolism: clinical and experimental, 2003, Volume: 52, Issue:9

    Topics: Adult; Black People; Blood Glucose; Body Constitution; Body Mass Index; C-Peptide; Chromans; Diabete

2003
Pharmacological treatment of insulin resistance at two different stages in the evolution of type 2 diabetes: impact on glucose tolerance and beta-cell function.
    The Journal of clinical endocrinology and metabolism, 2004, Volume: 89, Issue:6

    Topics: Adult; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Female; Glucose Intolerance; Hispanic or

2004
Effect of troglitazone on insulin sensitivity and pancreatic beta-cell function in women at high risk for NIDDM.
    Diabetes, 1996, Volume: 45, Issue:11

    Topics: Adult; Blood Glucose; Blood Pressure; Body Mass Index; California; Cholesterol, HDL; Cholesterol, LD

1996
Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone.
    Diabetes care, 1997, Volume: 20, Issue:2

    Topics: Adult; Aged; Blood Glucose; C-Peptide; Chromans; Double-Blind Method; Ethnicity; Glucose Intolerance

1997
Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance.
    The Journal of clinical investigation, 1997, Aug-01, Volume: 100, Issue:3

    Topics: Administration, Oral; Adult; Animals; Chromans; Double-Blind Method; Female; Glucose; Glucose Intole

1997
Trivalent chromium and the diabetes prevention program.
    Medical hypotheses, 1997, Volume: 49, Issue:1

    Topics: Chromans; Chromium; Clinical Protocols; Complementary Therapies; Diabetes Mellitus, Type 2; Diet; Ex

1997
Response of pancreatic beta-cells to improved insulin sensitivity in women at high risk for type 2 diabetes.
    Diabetes, 2000, Volume: 49, Issue:5

    Topics: Adult; Chromans; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Glucose; Glucose Intolera

2000
Thiazolidinedione derivative improves fat distribution and multiple risk factors in subjects with visceral fat accumulation--double-blind placebo-controlled trial.
    Diabetes research and clinical practice, 2001, Volume: 54, Issue:3

    Topics: Adipose Tissue; Blood Glucose; Blood Pressure; Body Composition; Cholesterol; Chromans; Double-Blind

2001

Other Studies

3 other studies available for troglitazone and Glucose Intolerance

ArticleYear
Is troglitazone a real indication for obese subjects with impaired glucose tolerance?
    Diabetes care, 1997, Volume: 20, Issue:8

    Topics: Chromans; Diabetes Mellitus, Type 2; Glucose Intolerance; Humans; Hypoglycemic Agents; Obesity; Thia

1997
Insulin action enhancement normalizes brachial artery vasoactivity in patients with peripheral vascular disease and occult diabetes.
    Journal of vascular surgery, 1998, Volume: 28, Issue:6

    Topics: Aged; Blood Flow Velocity; Brachial Artery; Chromans; Fasting; Glucose Intolerance; Glucose Toleranc

1998
Troglitazone ameliorates insulin resistance in a diabetic patient with Prader-Willi syndrome.
    Diabetes research and clinical practice, 1998, Volume: 42, Issue:3

    Topics: Adolescent; Blood Glucose; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 1; Glucose Intoleran

1998